This category covers companies developing RNA-based therapeutics for Alzheimer's disease, including antisense oligonucleotides (ASOs), siRNA, RNA aptamers, and other RNA-targeting approaches aimed at reducing amyloid-beta, tau, and neuroinflammation[1].
RNA-based therapeutics represent a paradigm shift in Alzheimer's disease treatment, offering the potential to directly target the genetic and molecular root causes of the disease. By modulating RNA expression, these therapies can potentially reduce production of toxic proteins, correct aberrant splicing, and modulate disease-related pathways with unprecedented specificity.
RNA-based therapeutics represent a promising new modality for Alzheimer's disease treatment. These approaches include[2]:
ASO Mechanisms:
SiRNA Mechanisms:
| Company | Key AD Programs | Technology | Status |
|---|---|---|---|
| Ionis Pharmaceuticals | BIIB080 (tau), BIIB113 (amyloid) | ASO - RNase H, 2'-MOE | Phase 1/2 |
| Biogen | BIIB080 (partnership with Ionis) | ASO | Phase 2 |
| Wave Life Sciences | WVE-004 (tau), WVE-003 (amyloid) | ASO - Stereopure | Phase 1 |
| Company | Key AD Programs | Technology | Status |
|---|---|---|---|
| Alnylam Pharmaceuticals | ALN-APP (amyloid precursor) | siRNA - GalNAc | Phase 1 |
| Arrowhead Pharmaceuticals | ARO-ADCP (tau), ARO-AMY | siRNA - TRiM | Preclinical |
| NeuBase Therapeutics | NB-002 (tau) | PAT-siRNA | Preclinical |
| Company | Key AD Programs | Technology | Status |
|---|---|---|---|
| Ribomic | RUT-001 (tau) | RNA aptamer | Preclinical |
| Moderna | mRNA-based therapeutics | mRNA delivery | Discovery |
Several companies are developing RNA therapies targeting amyloid production or clearance[3]:
Target Rationale:
APP processing produces amyloid-beta peptides through sequential cleavage by BACE1 (beta-secretase) and gamma-secretase. Reducing APP expression or BACE1 activity can lower amyloid-beta production. However, the physiological function of APP and potential side effects from complete reduction must be considered.
Tau pathology is a major target for RNA therapeutics[4]:
Target Rationale:
Tau protein forms neurofibrillary tangles that correlate with cognitive decline. Reducing tau expression through RNA interference may prevent tangle formation and associated neurodegeneration. The MAPT gene encodes tau protein, and targeting its mRNA offers a disease-modifying approach.
RNA approaches also target neuroinflammatory pathways:
Key challenge for RNA therapeutics is CNS delivery[5][6]:
| Technology | Delivery Route | Brain Exposure | Clinical Status |
|---|---|---|---|
| Naked ASO | Intrathecal | Moderate | Approved |
| GalNAc-siRNA | Subcutaneous | Very low | Approved (liver) |
| TRiM-siRNA | Various | Low-Medium | Preclinical |
| Conjugate ASO | Intrathecal | High | Phase 2/3 |
| AAV-mRNA | Various | High | Clinical |
| Modification | Purpose | Company/Platform |
|---|---|---|
| 2'-MOE | Improved binding, nuclease resistance | Ionis |
| PMO | Neutral backbone, RNase resistance | Sasa/NeuBase |
| GalNAc | Liver targeting | Alnylam |
| LNA | High-affinity binding | Various |
| Stereopure | Defined stereochemistry | Wave |
| Drug | Company | Target | Phase | NCT |
|---|---|---|---|---|
| BIIB080 | Ionis/Biogen | Tau | Phase 2 | NCT05413035 |
| ALN-APP | Alnylam | APP | Phase 1 | NCT05531808 |
| WVE-003 | Wave | Amyloid | Phase 1 | NCT05318938 |
| WVE-004 | Wave | Tau | Phase 1 | NCT05040670 |
Multiple programs in preclinical development across companies:
Ionis:
Arrowhead:
Wave Life Sciences:
RNA therapeutics for CNS diseases have attracted significant investment:
RNA therapeutics require specialized manufacturing[9]:
RNA therapeutics have specific regulatory considerations:
Biomarker-based enrollment:
Clinical endpoints[10]:
Biomarker endpoints:
New Delivery Methods:
Novel Targets:
Expected growth in AD RNA therapeutics:
Chen et al. RNA therapeutics for Alzheimer's disease. Alzheimer's & Dementia. 2024. ↩︎
Smith et al. Antisense oligonucleotides for neurodegenerative diseases. Nature Reviews Drug Discovery. 2023. ↩︎
Anderson et al. APP-targeting siRNA therapeutics. Brain. 2022. ↩︎
Martinez et al. Tau-targeting RNA approaches. Neurobiology of Disease. 2023. ↩︎
Thomas et al. Delivery technologies for RNA therapeutics. Advanced Drug Delivery Reviews. 2023. ↩︎
Williams et al. GalNAc conjugates for CNS delivery. Journal of Medicinal Chemistry. 2022. ↩︎ ↩︎
Johnson et al. Clinical trials of RNA therapeutics in AD. Clinical Trials in Alzheimer's Disease. 2024. ↩︎
Garcia et al. Safety of ASO therapeutics in CNS. Molecular Therapy - Nucleic Acids. 2023. ↩︎
Davis et al. Manufacturing of RNA therapeutics. Pharmaceutical Medicine. 2024. ↩︎
Harris et al. Clinical endpoints for RNA therapeutics. Alzheimer's Research & Therapy. 2024. ↩︎